|
|
|
Top 5 Notable Abstracts in the Small Cell Lung Cancer and Stage I-III NSCLC Track
Here are the 5 presentations at ASCO in stage I-III NSCLC and small cell lung cancer that I think are most interesting and relevant. You’ll note that several are “negative” trials — blockbusters are hard to come by here — but even trials that tell us what not to do are important. And there are some hints of new approaches that could improve outcomes for patients.
My Top 5 Notable ASCO 2012 Abstracts in Metastatic NSCLC
The annual conference of the American Society of Clinical Oncology in late spring is the biggest event in the cancer world, where more of the big trials are presented than at any other time all year. In the lung cancer world, it’s looking like this one won’t be a blockbuster but will have some promising and interesting findings to discuss. As a preview, I wanted to offer my top 5 for what I think will emerge as the most important results we’ll see, based on the recently released abstracts of the meeting. Lung cancer is divided into two tracks: today, I’ll cover the metastatic lung cancer track, and then I’ll next offer a top 5 on the track covering stage I-III NSCLC, SCLC, and other less common thoracic cancers
Without further adieu, here are my top 5 in metastatic NSCLC: Continue reading
Molecular Markers, Part 5: Dr. David Spigel on Integrating Markers into Clinical Trials
Here’s part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity. In this podcast, my friend Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN presents on the benefits as well as the challenges of new models of clinical trials in lung cancer that move away from “all comers” to smaller, more limited populations defined by molecular markers. Following his presentation, we continued our panel discussion, covering how much the transition into molecular oncology has disrupted how we do clinical research, as well as how our growing experience with molecular testing is leading us to question some of our previously held beliefs.
Below are the audio and video versions of this podcast, along with the transcript and figures for it.
Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Audio Podcast
Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Transcript
Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Figs
Podcast: Play in new window | Download (Duration: 24:30 — 57.3MB) | Embed
Ongoing Great Panel Discussion from the Santa Monica Molecular Markers Webinar: Part 4
Here’s the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss. We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.
Below you’ll find the audio and video versions of the podcast, along with the transcript (no real figures to go with this one).
Molecular Markers SM Pt 4 Panel Discussion Audio Podcast
Molecular Markers SM Pt 4 Panel Discussion Transcript
We’ll continue with a presentation by Dr. Spigel on the value and challenges of incorporating molecular markers into the design of clinical trials in lung cancer.
Podcast: Play in new window | Download (Duration: 16:57 — 32.1MB) | Embed
Molecular Markers Webinar Part 3: Panel Discussion Debating Who to Test and What to Test For:
Here is the next portion of our special webinar on molecular markers in advanced NSCLC, featuring Drs. Charlie Rudin from Johns Hopkins, Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Glen Goss from the University of Ottawa and NCI-Canada’s Lung Cancer Committee.
In this continuing portion of the program, we have a debate on the merits of uniform vs. more selective testing of “druggable” mutations and consider whether it is more attractive to test for multiple markers simultaneous or perhaps sequentially, since they are typically mutually exclusive. We also discuss the challenge of the delays in treatment that may become a real clinical problem for some patients if testing may require a few weeks of downtime.
Below you’ll find the audio and video versions of the podcast, along with the transcript and figures for this activity.
Molecular Markers SM Pt 3 Panel Discussion Audio Podcast
Molecular Markers SM Pt 3 Panel Discussion Transcript
Molecular Markers SM Pt 3 Panel Discussion Figs
Podcast: Play in new window | Download (Duration: 17:28 — 38.3MB) | Embed
Dr. Alice Shaw on Clinical Factors Associated with Molecular Markers
I’m happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on “Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?“, in which I was joined by Drs. Charles Rudin (Johns Hopkins University in Balimore, MD), Alice Shaw (Massachusetts General Hospital in Boston, MA), David Spigel (Sarah Cannon Cancer Center in Nashville, TN), and Glen Gloss (University of Ottawa in Ontario, Canada).
In this short podcast, Dr. Alice Shaw reviewed the frequencies of different molecular markers in advanced NSCLC as a function of patient sex, smoking status, race, and tumor histology. This work is very interesting, of course, because if we only do molecular marker studies of people with an adenocarcinoma or never-smokers, we not only won’t ever find potentially relevant mutations in people with other histologies and those with a smoking history, but we won’t have any good idea of the probabilities of finding them either.
Here is the podcast in audio and video formats, as well as the transcript and figures.
Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Audio Podcast
Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Transcript
Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Figs
Podcast: Play in new window | Download (Duration: 10:48 — 24.9MB) | Embed
Molecular Markers in Lung Cancer: Dr. Charlie Rudin on the Lung Cancer Mutation Consortium
This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica “Targeted Therapies in Lung Cancer” meeting several weeks ago. There, I was privileged to be joined by four excellent guest faculty members — Dr. Charles Rudin from Johns Hopkins University in Baltimore, Dr. Alice Shaw from Massachusetts General Hospital in Boston, Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, and Dr. Glen Goss from the University of Ottawa. They each brought their rich experience and some differing perspectives on the complex and evolving topic of how to apply new work on molecular markers in lung cancer to clinical practice.
Below you’ll find links to the audio and video versions of the podcast, along with the transcript and figures.
Molecular Markers SM Pt 1 Rudin on LCMC Audio Podcast
Molecular Markers SM Pt 1 Rudin on LCMC Transcript
Molecular Markers SM Pt 1 Rudin on LCMC Figures
Podcast: Play in new window | Download (Duration: 17:36 — 40.6MB) | Embed
Question and Answer Session with Dr. Weiss on Lung Cancer Highlights, 2011
Here’s the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 — the question and answer session that followed his presentation. Below is the transcript, figures, and the audio and video versions of the podcast.
Dr. Weiss Lung Cancer Highlights 2011 Q and A Transcript
Dr. Weiss Lung Cancer Highlights 2011 Q and A Session Figs
Dr. Weiss Lung Cancer Highlights 2011 Q and A Session Audio Podcast
Podcast: Play in new window | Download (Duration: 18:14 — 40.0MB) | Embed
2011 Highlights in Lung Cancer, by Dr. Jared Weiss, Part 1: The EGFR Axis
Apologies for the long wait since our own Dr. Weiss’s upbeat and thoughtful review of the leading stories about lung cancer in 2011. Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, so we’ve broken that up into several short pieces that cover a few highlights at a time. In fact, we’re going to make an effort to have podcasts shorter and easier to digest in the future.
The first part is on EGFR-based therapies, including the EURTAC trial of the EGFR tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) vs. standard doublet chemo in a European, EGFR mutation-positive patient population, followed by work on EGFR TKI/monoclonal antibody combinations: one being the single arm afatinib/Erbitux (cetuximab) for patients with acquired resistance after a good response to earlier EGFR TKI therapy, and the second being Tarceva with either the c-MET antibody MET-MAb or placebo.
Here’s the audio and video versions of the podcast, along with the transcript and figures for this portion of the program.
Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Audio Podcast
Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Transcript
Dr. Weiss Lung Cancer Highlights 2011 Pt 1 EGFR Axis Figs
Podcast: Play in new window | Download (Duration: 11:13 — 39.1MB) | Embed
Five Key Insights from the Targeted Therapies in Lung Cancer Meeting
I’m just now returning from the International Association for the Study of Lung Cancer’s “12th Annual Targeted Therapies in Lung Cancer Conference”, which consisted of about 170 very brief talks about several classes of agents, as I described in my last post. Some of these are likely to emerge as viable, truly beneficial therapies for patients; many others will fall by the wayside. Because it’s really not feasible to discuss such a broad range of agents that we only get a snapshot view of, I thought I’d try to convey what emerged as five core takeaway points from the 2012 iteration of this important meeting.
| Follow us on... |    |
||
Copyright ©2012 GRACE |
|||